Beate Kampmann
As seen in:
Color Research & Application,
Nature,
Daily Express,
Der Tagesspiegel,
The Conversation,
Thorax,
Medical Xpress,
Cell Press,
Inverse,
The Lancet
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Beate Kampmann
Mucosal IgA to pre-fusion F protein predicts protection from RSV infection in a high burden setting
Abstract Respiratory syncytial virus (RSV) causes over 100,000 annual deaths, predominantly in low- and middle-income countries, yet immunological correlates of protection remain poorly defined in high-burden settings. This study aims to identify immunological correlates of protection against RSV infection, and to compare the relative contribution of systemic and mucosal antibody responses.
Population-specific heterogeneity in ontogeny of the broadly-conserved blood transcriptional program during the first week of life
|
Abstract Previous research has shown that immune development during the first week of life, i.e. ontogeny, is progressive, consistent and robust, involving large numbers of differentially expressed genes at each sampled time point.
By Bhavjinder K Dhillon, Travis Blimkie, Olubukola Idoko, Rebecca Ford, Asimenia Angelidou, Rym Ben-Othman, Sebastiano Montante, Nelly Amenyogbe, Joann Diray-Arce, Reza Falsafi, Abdulazeez Imam, Kerry McEnaney, Oludare A. Odumade, Al Ozonoff, William S Pomat, Peter Richmond, Kinga K. Smolen, Oghenebrume Wariri, Ofer Levy, Anita van den Biggelaar, Beate Kampmann, Tobias R. Kollmann, Amy Lee, Robert E. W. Hancock, Tida Dibassey
|
Nature
Verified
Ebola vaccine safe for mothers and infants - Nature Medicine
A clinical trial of pregnant women provides critical safety and immunogenicity data in support of a two-dose Ebola vaccine regimen — and reinforces the importance of maternal immunization research, urgently needed for other preventable diseases.
Publisher Correction: Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting | Nature Medicine
Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-03868-4, published online 8 August 2025. In the version of the article initially published, in the “Early-life serological profiles” section, the text “…two or more antigens of greater than 0.5 log10 RLU ml−1” should have read “…two or more antigens or greater than 0.5 log10 RLU ml−1”.
Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting - Nature Medicine Original
Abstract Streptococcus pyogenes leads to 500,000 deaths annually, many due to rheumatic heart disease in low-income settings. Limited understanding of natural protective immunity to S. pyogenes hinders vaccine development. Here we describe the evolution of serological profiles to conserved vaccine antigens and serotype-specific M proteins from birth and throughout the life course in The Gambia.
Covid-19 als Urlaubserinnerung: Wie groß ist die Gefahr, sich im Ausland mit Corona anzustecken?
© IMAGO/Zoonar/Bearbeitung Tagesspiegel Während der Ferienzeit reisen viele Menschen ins Ausland. Doch dort ist die Coronasituation oft eine andere, als in Deutschland. Sollte man am Urlaubsort besondere Schutzmaßnahmen einhalten? Von Ingo Bach Beate Kampmann Natalie Nidens Heute, 11:47 Uhr Corona ist immer noch da, auch wenn inzwischen weltweit die Menschen längst erleichtert zur Tagesordnung übergegangen sind, weil die Pandemie scheinbar zu Ende ist.
Access to respiratory syncytial virus preventive tools for neonates and infants in Europe
Respiratory syncytial virus (RSV) is responsible for an estimated 33 million cases of pneumonia and more than 100 000 deaths annually in children younger than 5 years.For the past two decades, the monoclonal antibody palivizumab has been the only available preventive option against RSV.The cost and limited half-life of palivizumab, which requires five injections per season, have restricted its use to children with a high risk of infection.
No one is safe until everyone is safe-from polio too
Ed Clarke, principal investigator and consultant paediatrician12, Beate Kampmann, professor of paediatric infection and immunity and director, theme leader for vaccines and immunity research12 1The Vaccine Centre, London School of Hygiene and Tropical Medicine 2Vaccines & Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine The detection of polioviruses in the UK should remind us once again that viruses know no borders, write Ed Clarke and Beate Kampmann...
Making a case for investing in post-tuberculosis lung health in children
Over the past two decades, more than 66 million lives have been saved through global efforts to curb the tuberculosis pandemic. With intensified efforts to improve active case finding and enable prompt diagnosis and early treatment initiation, we can expect this number to increase over the next few years. As we commemorate World TB Day on March 24, 2022, nearly 3000 children worldwide still contract this preventable disease every day. This article is available free of charge.
Prioritising immunisation across the life course
We read with interest the paper by Kate Causey and colleagues, the first detailed quantification of the substantial disruptions to routine childhood immunisations throughout the COVID-19 pandemic.
COVID-19 vaccines for children in LMICs: another equity issue
Given the success of COVID-19 vaccines in preventing death and severe disease in adults 1 Haas EJ Angulo FJ McLaughlin JM et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397: 1819-1829 and their impact on community transmission, 2 Harris RJ Hall JA Zaidi A et al.
Covid-19 vaccines save lives
Intended for healthcare professionals Toggle navigation The BMJ logo Toggle top menu News & Views Covid-19 vaccines save...
The need to prioritise childhood tuberculosis case detection
1 WHO Resolution WHA67.1. Global strategy and targets for tuberculosis prevention, care and control after 2015. World Health Organization, Geneva2014 little progress has been made. The COVID-19 pandemic has worsened the situation because of its negative impact on tuberculosis case detection and reduced access to tuberculosis treatment and prevention services globally.
An interactive website tracking COVID-19 vaccine development
The past year has seen the rapid global spread of SARS-CoV-2—the virus responsible for the ongoing COVID-19 pandemic. While non-pharmaceutical interventions have been the mainstay of epidemic control to date, vaccination is likely to constitute the definitive, long-term defence strategy against SARS-CoV-2 morbidity, mortality, and transmission, offering the best hope of a return to normal life.
Women and children last? Shaking up exclusion criteria for vaccine trials
Is it time to shift to a model of ‘inclusion unless otherwise justified’ in trials of vaccines for pandemics? The COVID-19 pandemic has turned many things on its head, including routine approaches to the development of vaccines. The urgency of the pandemic has meant that the lengthy timelines of clinical trials, stepwise adaptations and eventual programmatic rollouts via primary-care systems have been truncated to achieve rapid development.
Keeping track of the SARS-CoV-2 vaccine pipeline
When will we have an effective vaccine against SARS-CoV-2? There can be few questions with more profound implications for what life will look like over the coming years. On the one hand, there is a blunt and unsatisfying answer: until the results of large-scale efficacy trials are available, we simply cannot know. On the other hand, there is cause for optimism. This year has seen a remarkable mobilization of resources, ingenuity and dedication from vaccine researchers across the globe.
Performance of metabonomic serum analysis for diagnostics in paediatric tuberculosis
Abstract We applied a metabonomic strategy to identify host biomarkers in serum to diagnose paediatric tuberculosis (TB) disease. 112 symptomatic children with presumptive TB were recruited in The Gambia and classified as bacteriologically-confirmed TB, clinically diagnosed TB, or other diseases. Sera were analysed using 1H nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). Multivariate data analysis was used to distinguish patients with TB from other diseases.
COVID-19 treatment might already exist in old drugs – we’re using pieces of the coronavirus itself to find them
Why don’t we have drugs to treat COVID-19 and how long will it take to develop them? SARS-CoV-2 – the coronavirus that causes the disease COVID-19 – is completely new and attacks cells in a novel way. Every virus is different and so are the drugs used to treat them. That’s why there wasn’t a drug ready to tackle the new coronavirus that only emerged a few months ago.
Ibuprofen and COVID-19 symptoms - here’s what you need to know
There’s been some confusion recently on whether we should or shouldn’t take ibuprofen to treat symptoms of COVID-19 – especially after the World Health Organization (WHO) changed its stance. After initially recommending people avoid taking ibuprofen to treat symptoms of the new coronavirus disease, as of March 19 the WHO now does not recommend avoiding ibuprofen to treat COVID-19 symptoms.
Should I test my gut microbes to improve my health?
People are paying hundreds of dollars to have their gut microbes analyzed, hoping the insights will allow them to adjust their diet and improve their health. But these testing services are based on science that’s still in its infancy, as we explain in our recent paper. So while there may be great promise for analyzing our gut microbiome to help diagnose and treat people in the future, for the moment knowing what’s in your gut is mostly a curiosity. But aren’t these tests based on science?
The burden of viral respiratory infections in young children in low-resource settings
Acute lower respiratory infections (ALRI), encompassing bacterial and viral pneumonias, acute viral bronchiolitis, and bacterial and viral bronchitis, remain the leading cause of global child mortality. 1 UN Inter-agency Group for Child Mortality Estimation Levels & trends in child mortality: report 2019, estimates developed by the UN Inter-agency Group for Child Mortality Estimation.
How to know who's at risk?
Coronavirus: How To Know Who's At Risk? SHARE, SAVE, COMMENT Here's how social distancing works: The pattern that needs to be aimed for is: contain, delay, research, and mitigate.(Photo: AP) Edward ParkerBeate Kampmann00H 03M AGO For many of us, the threat of coronavirus suddenly feels much closer to home. The last few days have seen a rapid increase in the number of cases in South Korea, Iran and Italy.
InnerSelf
Welcome... Our InnerSelf welcomes your inner self. This is the early-bird version of the newsletter/new issue of InnerSelf. The complete version will be online, and emailed to subscribers, late Sunday afternoon. Insightful reading! Please scroll down for the featured articles in this new issue of InnerSelf, and also the recap of all the articles that were added to the website during the week. Wishing you enjoyable insightful reading, and of course a wonder-full, joy-full, and loving week. Marie T.
Coronavirus: Who is at risk and how do we know?
Credit: Alejandro Bascuas/Shutterstock For many of us, the threat of coronavirus suddenly feels much closer to home. The last few days have seen a rapid increase in the number of cases in South Korea, Iran and Italy. Now officially a pandemic, the virus has proven adept at crossing borders, with confirmed cases reported in over 100 countries (for the latest numbers, refer to our coronavirus mapping tool).
Who Is At Risk Of Coronavirus And How Do We Know?
Alejandro Bascuas/Shutterstock For many of us, the threat of coronavirus suddenly feels much closer to home. The last few days have seen a rapid increase in the number of cases in South Korea, Iran and Italy. Now officially a pandemic, the virus has proven adept at crossing borders, with confirmed cases reported in over 100 countries (for the latest numbers, refer to our coronavirus mapping tool). In the face of this escalating outbreak, it can be difficult to gauge how concerned we should be.
Coronavirus: who is at risk and how do we know?
For many of us, the threat of coronavirus suddenly feels much closer to home. The last few days have seen a rapid increase in the number of cases in South Korea, Iran and Italy. Now officially a pandemic, the virus has proven adept at crossing borders, with confirmed cases reported in over 100 countries (for the latest numbers, refer to our coronavirus mapping tool). In the face of this escalating outbreak, it can be difficult to gauge how concerned we should be.
The evolving research agenda for paediatric tuberculosis infection
Summary Following exposure to tuberculosis and subsequent infection, children often progress to tuberculosis disease more rapidly than adults. And yet the natural history of tuberculosis in children, as a continuum from exposure to infection and then to disease, is poorly understood. Children are rarely diagnosed with tuberculosis infection in routine care in international settings and few receive tuberculosis infection treatment.
Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials
Summary Background A meningococcal group A conjugate vaccine, PsA-TT (also known as MenAfriVac), was developed with the support of the Meningitis Vaccine Project. Around 280 million individuals aged 1–29 years have been immunised across the African meningitis belt. We analysed the kinetics of vaccine-induced antibody response and assessed the possible implications for duration of protection.
Serocorrelates of protection against infant group B streptococcus disease
References Sigauque B Kobayashi M Vubil D et al. Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001–2015. PLoS One. 2018; 13: e0191193 Schrag S Gorwitz R Fultz-Butts K Schuchat A Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep.
Tuberculosis susceptibility and protection in children
Children represent both a clinically important population susceptible to tuberculosis and a key group in whom to study intrinsic and vaccine-induced mechanisms of protection. After exposure to Mycobacterium tuberculosis, children aged under 5 years are at high risk of progressing first to tuberculosis infection, then to tuberculosis disease and possibly disseminated forms of tuberculosis, with accompanying high risks of morbidity and mortality.
Biomarkers for diagnosis of childhood tuberculosis: A systematic review
We found that majority of the biomarkers for diagnosis of TB in children are promising but will need further refining and optimization to improve their performances. As new data are emerging, stronger emphasis should be placed on improving the design, quality and general reporting of future studies investigating TB biomarkers in children. The 29 studies included in this systematic review comprise 20 case-control studies, six cohort studies and three cross-sectional studies.
The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review
Summary The burden of influenza in Africa is substantial and underappreciated. Although surveillance has increased, the medical community's understanding of seasonal influenza vaccine performance remains limited. We did a systematic review, using PRISMA guidelines (PROSPERO CRD42017058107), on the efficacy, effectiveness, and immunogenicity of influenza vaccines in populations within Africa with the aim of identifying key data gaps to help direct future research.
Short course treatment for MDR TB: jumping the gun?
Multidrug-resistant (MDR)-TB is threatening TB control worldwide. The conventional treatment lasts 20–24?months, is often toxic and half of the treated patients have poor outcomes.
Short course treatment for MDR TB: jumping the gun?
Multidrug-resistant (MDR)-TB is threatening TB control worldwide. The conventional treatment lasts 20–24?months, is often toxic and half of the treated patients have poor outcomes.
Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny
To use the Enhanced view of this article, please enable JavaScript on in your browser and refresh the page. ReviewProtecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny Tobias R. KollmannxTobias R.
Immunological consequences of strain variation within the Mycobacterium Tuberculosis complex
In 2015 there were an estimated 10.4 million new cases of Tuberculosis (TB) globally, making it one of the leading causes of death due to an infectious disease. TB is caused by members of the Mycobacterium tuberculosis complex (MTBC), with human disease resulting from infection by M. tuberculosis sensu strico and M. africanum.
Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ
Research ArticleImmunology Free access | 10.1172/JCI19316 Beate Kampmann,1 Cheryl Hemingway,1 Alick Stephens,1 Robert Davidson,2 Anna Goodsall,1 Suzanne Anderson,1 Mark Nicol,3 Elisabeth Schölvinck,1 David Relman,4 Simon Waddell,4 Paul Langford,1 Brian Sheehan,1 Lynn Semple,3 Katalin A. Wilkinson,1 Robert J. Wilkinson,2 Stanley Ress,3 Martin Hibberd,1 and Michael Levin5 1Department of Paediatrics and Wellcome Centre for Clinical Tropical Medicine, Imperial College London, London, United Kingdom.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Beate
Contact Beate, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack